Release date: 2025-04-18 10:32:52 Article From: Lucius Laos Recommended: 36
Focusing on the clinical value of finerenone, the medical community is conducting in-depth discussions.
The drug reduces the rate of protein excretion by selectively inhibiting mineralocorticoid receptors.
Data from the phase III clinical trial showed an average reduction of 31% in urine protein levels and a 29% slowdown in the decline of kidney function.
It is mainly for patients with type 2 diabetes who have chronic metabolic problems. The inclusion criteria of the study showed that the glomerular filtration rate of the subjects should be in the range of 25-75ml/min/1.73m² with microproteinuria.
The daily cost of medication is about $4.2, and the annual cost of treatment is about $1,500. It is important to note that actual expenditures may fluctuate depending on dose adjustments or adjuvant therapy.
Treatment decisions need to be made in conjunction with individualized medical needs.
Compared with spironolactone, the incidence of electrolyte abnormalities was reduced by 40%. Compared with eplerenone, it lowers blood pressure by 15%, but serum potassium levels need to be monitored regularly.
Dietary intervention delayed medication requirements in 24% of patients. 150 minutes of moderate-intensity exercise per week combined with a low-sodium diet improved urine protein by 18% in some cases.
Electrolytes are measured every two weeks at the beginning of treatment and monthly when they are stable. For special populations, it is recommended to start with half a dose and gradually adjust to the target dose.
Medical decisions should be based on a comprehensive assessment, with regular testing and dynamic adjustments constituting key elements of treatment success. Personalized solutions under the guidance of a professional team can maximize the desired treatment goals.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: